{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:33:30Z","timestamp":1794105210183,"version":"4.8.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ak0101188"],"award-info":[{"award-number":["JP22ak0101188"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ak0101280"],"award-info":[{"award-number":["JP25ak0101280"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Molecular interactions between therapeutic antibodies and neonatal Fc receptor (FcRn) are major contributors to the long serum half-life of antibodies. Therefore, the in vitro affinity of IgG for FcRn is an important indicator of in vivo pharmacokinetic properties. However, the molecular basis of IgG-FcRn interactions is not fully understood from experimental and structural perspectives. Affinity evaluation using surface plasmon resonance is difficult. The molecular mechanism by which domains other than Fc or surface charges affect FcRn binding remains unclear. In this study, we developed an engineered FcRn-immobilized column for affinity chromatography. We analyzed various types of antibodies to link physicochemical characteristics and FcRn affinity. Furthermore, analysis using charge-engineered mutants indicated that the lateral surface of L chain also affects the FcRn affinity. Finally, we presented a structural model of the IgG-FcRn complex to discuss the molecular mechanism of how the charges at L chain affect the FcRn affinity.<\/jats:p>","DOI":"10.1038\/s42003-026-09789-3","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T13:33:43Z","timestamp":1772544823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatography"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-8138","authenticated-orcid":false,"given":"Masato","family":"Kiyoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruaki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linko","family":"Hirono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiko","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-3963","authenticated-orcid":false,"given":"Satoru","family":"Nagatoishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-5164","authenticated-orcid":false,"given":"Kouhei","family":"Tsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ishii-Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"9789_CR1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2297450","volume":"16","author":"S Crescioli","year":"2024","unstructured":"Crescioli, S. et al. Antibodies to watch in 2024. mAbs 16, 2297450 (2024).","journal-title":"mAbs"},{"key":"9789_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2018","unstructured":"Carter, P. J. & Lazar, G. A. Next generation antibody drugs: pursuit of the \u2018high-hanging fruit. Nat. Rev. Drug Discov. 17, 197\u2013223 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9789_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody-drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22, 641\u2013661 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9789_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9789_CR5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","volume":"22","author":"RE Kontermann","year":"2011","unstructured":"Kontermann, R. E. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 22, 868\u2013876 (2011).","journal-title":"Curr. Opin. Biotechnol."},{"key":"9789_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer, R. J., Huitema, A. D., Schellens, J. H. & Beijnen, J. H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. pharmacokinet. 49, 493\u2013507 (2010).","journal-title":"Clin. pharmacokinet."},{"key":"9789_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","volume":"52","author":"M Dostalek","year":"2013","unstructured":"Dostalek, M., Gardner, I., Gurbaxani, B. M., Rose, R. H. & Chetty, M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin. pharmacokinet. 52, 83\u2013124 (2013).","journal-title":"Clin. pharmacokinet."},{"key":"9789_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715\u2013725 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"9789_CR9","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMra2312718","volume":"392","author":"JB Bussel","year":"2025","unstructured":"Bussel, J. B., Cines, D. B. & Blumberg, R. S. Neonatal Fc receptor\u2014biology and therapeutics.  N. Engl. J. Med. 392, 1621\u20131635 (2025).","journal-title":"N. Engl. J. Med."},{"key":"9789_CR10","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1074\/jbc.M114.603712","volume":"290","author":"MJ Borrok","year":"2015","unstructured":"Borrok, M. J. et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.  J. Biol. Chem. 290, 4282\u20134290 (2015).","journal-title":"J. Biol. Chem."},{"key":"9789_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103746","volume":"25","author":"A Grevys","year":"2022","unstructured":"Grevys, A. et al. Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life. iScience 25, 103746 (2022).","journal-title":"iScience"},{"key":"9789_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/19420862.2015.1016696","volume":"7","author":"A Datta-Mannan","year":"2015","unstructured":"Datta-Mannan, A. et al. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. mAbs 7, 483\u2013493 (2015).","journal-title":"mAbs"},{"key":"9789_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule, N., Jawa, V. & Meibohm, B. Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy.  AAPS J. 14, 296\u2013302 (2012).","journal-title":"AAPS J."},{"key":"9789_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1995929","volume":"13","author":"E Opolka-Hoffmann","year":"2021","unstructured":"Opolka-Hoffmann, E. et al. The impact of immunogenicity on therapeutic antibody pharmacokinetics: a preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance. mAbs 13, 1995929 (2021).","journal-title":"mAbs"},{"key":"9789_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2361585","volume":"16","author":"J Reusch","year":"2024","unstructured":"Reusch, J., Andersen, J. T., Rant, U. & Schlothauer, T. Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn. mAbs 16, 2361585 (2024).","journal-title":"mAbs"},{"key":"9789_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/372336a0","volume":"372","author":"WP Burmeister","year":"1994","unstructured":"Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L. & Bjorkman, P. J. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature 372, 336\u2013343 (1994).","journal-title":"Nature"},{"key":"9789_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/372379a0","volume":"372","author":"WP Burmeister","year":"1994","unstructured":"Burmeister, W. P., Huber, A. H. & Bjorkman, P. J. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372, 379\u2013383 (1994).","journal-title":"Nature"},{"key":"9789_CR18","doi-asserted-by":"publisher","first-page":"9698","DOI":"10.1021\/bi000749m","volume":"39","author":"AP West Jr","year":"2000","unstructured":"West, A. P. Jr & Bjorkman, P. J. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry 39, 9698\u20139708 (2000).","journal-title":"Biochemistry"},{"key":"9789_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1097-2765(01)00230-1","volume":"7","author":"WL Martin","year":"2001","unstructured":"Martin, W. L., West, A. P. Jr, Gan, L. & Bjorkman, P. J. Crystal structure at 2.8 A of an FcRn\/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell 7, 867\u2013877 (2001).","journal-title":"Mol. Cell"},{"key":"9789_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1074\/mcp.M116.064675","volume":"16","author":"PF Jensen","year":"2017","unstructured":"Jensen, P. F. et al. A Two-pronged binding mechanism of IgG to the neonatal Fc receptor controls complex stability and IgG serum half-life. Mol. Cell. Proteom. MCP 16, 451\u2013456 (2017).","journal-title":"Mol. Cell. Proteom. MCP"},{"key":"9789_CR21","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s42003-022-03787-x","volume":"5","author":"TT Gjolberg","year":"2022","unstructured":"Gjolberg, T. T. et al. Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life. Commun. Biol. 5, 832 (2022).","journal-title":"Commun. Biol."},{"key":"9789_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s42003-025-08252-z","volume":"8","author":"E Trabjerg","year":"2025","unstructured":"Trabjerg, E. et al. Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation. Commun. Biol. 8, 922 (2025).","journal-title":"Commun. Biol."},{"key":"9789_CR23","first-page":"1098","volume":"10","author":"BJ Booth","year":"2018","unstructured":"Booth, B. J. et al. Extending human IgG half-life using structure-guided design. mAbs 10, 1098\u20131110 (2018).","journal-title":"mAbs"},{"key":"9789_CR24","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","volume":"10","author":"M Pyzik","year":"2019","unstructured":"Pyzik, M. et al. The neonatal Fc receptor (FcRn): a misnomer? Front. Immunol. 10, 1540 (2019).","journal-title":"Front. Immunol."},{"key":"9789_CR25","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.4049\/jimmunol.0903296","volume":"184","author":"T Suzuki","year":"2010","unstructured":"Suzuki, T. et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. 184, 1968\u20131976 (2010).","journal-title":"J. Immunol."},{"key":"9789_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33764-1","volume":"13","author":"M Brinkhaus","year":"2022","unstructured":"Brinkhaus, M. et al. The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement. Nat. Commun. 13, 6073 (2022).","journal-title":"Nat. Commun."},{"key":"9789_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1993769","volume":"13","author":"S Liu","year":"2021","unstructured":"Liu, S., Verma, A., Kettenberger, H., Richter, W. F. & Shah, D. K. Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies. mAbs 13, 1993769 (2021).","journal-title":"mAbs"},{"key":"9789_CR28","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.4049\/jimmunol.2000732","volume":"205","author":"S Rossini","year":"2020","unstructured":"Rossini, S. et al. V region of IgG controls the molecular properties of the binding site for neonatal FC receptor. J. Immunol. 205, 2850\u20132860 (2020).","journal-title":"J. Immunol."},{"key":"9789_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2232087","volume":"15","author":"R Ollier","year":"2023","unstructured":"Ollier, R. et al. Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework. mAbs 15, 2232087 (2023).","journal-title":"mAbs"},{"key":"9789_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/19420862.2017.1389355","volume":"10","author":"NM Piche-Nicholas","year":"2018","unstructured":"Piche-Nicholas, N. M. et al. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. mAbs 10, 81\u201394 (2018).","journal-title":"mAbs"},{"key":"9789_CR31","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1073\/pnas.1408766112","volume":"112","author":"A Schoch","year":"2015","unstructured":"Schoch, A. et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc. Natl. Acad. Sci. USA 112, 5997\u20136002 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9789_CR32","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4161\/mabs.24981","volume":"5","author":"T Schlothauer","year":"2013","unstructured":"Schlothauer, T. et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. mAbs 5, 576\u2013586 (2013).","journal-title":"mAbs"},{"key":"9789_CR33","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.4161\/mabs.29601","volume":"6","author":"J Stracke","year":"2014","unstructured":"Stracke, J. et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. mAbs 6, 1229\u20131242 (2014).","journal-title":"mAbs"},{"key":"9789_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/19420862.2015.1008353","volume":"7","author":"YN Abdiche","year":"2015","unstructured":"Abdiche, Y. N. et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. mAbs 7, 331\u2013343 (2015).","journal-title":"mAbs"},{"key":"9789_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/protein\/gzq009","volume":"23","author":"T Igawa","year":"2010","unstructured":"Igawa, T. et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng. Des. Sel. PEDS 23, 385\u2013392 (2010).","journal-title":"Protein Eng. Des. Sel. PEDS"},{"key":"9789_CR36","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.4155\/bio-2017-0109","volume":"9","author":"F Cymer","year":"2017","unstructured":"Cymer, F., Schlothauer, T., Knaupp, A. & Beck, H. Evaluation of an FcRn affinity chromatographic method for IgG1-type antibodies and evaluation of IgG variants. Bioanalysis 9, 1305\u20131317 (2017).","journal-title":"Bioanalysis"},{"key":"9789_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03061-x","volume":"9","author":"A Grevys","year":"2018","unstructured":"Grevys, A. et al. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat. Commun. 9, 621 (2018).","journal-title":"Nat. Commun."},{"key":"9789_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1923366","volume":"13","author":"T Suzuki","year":"2021","unstructured":"Suzuki, T., Hashii, N., Tada, M. & Ishii-Watabe, A. The influence of antibody engineering on Fc conformation and Fc receptor binding properties: analysis of FcRn-binding engineered antibodies and an Fc fusion protein. mAbs 13, 1923366 (2021).","journal-title":"mAbs"},{"key":"9789_CR39","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.str.2013.08.022","volume":"21","author":"MM Schmidt","year":"2013","unstructured":"Schmidt, M. M. et al. Crystal structure of an HSA\/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure 21, 1966\u20131978 (2013).","journal-title":"Structure"},{"key":"9789_CR40","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1021\/bc100261d","volume":"21","author":"CA Boswell","year":"2010","unstructured":"Boswell, C. A. et al. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjugate Chem. 21, 2153\u20132163 (2010).","journal-title":"Bioconjugate Chem."},{"key":"9789_CR41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4161\/mabs.2.6.13333","volume":"2","author":"LA Khawli","year":"2010","unstructured":"Khawli, L. A. et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2, 613\u2013624 (2010).","journal-title":"mAbs"},{"key":"9789_CR42","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1600-0854.2009.00887.x","volume":"10","author":"Z Gan","year":"2009","unstructured":"Gan, Z., Ram, S., Vaccaro, C., Ober, R. J. & Ward, E. S. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 10, 600\u2013614 (2009).","journal-title":"Traffic"},{"key":"9789_CR43","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature07255","volume":"455","author":"W He","year":"2008","unstructured":"He, W. et al. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature 455, 542\u2013546 (2008).","journal-title":"Nature"},{"key":"9789_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1802135","volume":"12","author":"Y Sun","year":"2020","unstructured":"Sun, Y., Estevez, A., Schlothauer, T. & Wecksler, A. T. Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity. mAbs 12, 1802135 (2020).","journal-title":"mAbs"},{"key":"9789_CR45","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/protein\/gzs053","volume":"25","author":"Y Asaoka","year":"2012","unstructured":"Asaoka, Y., Hatayama, K., Tsumoto, K., Tomita, M. & Ide, T. Engineering of recombinant human Fcgamma receptor I by directed evolution. Protein Eng. Des. Sel. PEDS 25, 835\u2013842 (2012).","journal-title":"Protein Eng. Des. Sel. PEDS"},{"key":"9789_CR46","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.molimm.2009.02.002","volume":"46","author":"A Bertolotti-Ciarlet","year":"2009","unstructured":"Bertolotti-Ciarlet, A. et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol. Immunol. 46, 1878\u20131882 (2009).","journal-title":"Mol. Immunol."},{"key":"9789_CR47","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.molimm.2007.07.012","volume":"45","author":"H Liu","year":"2008","unstructured":"Liu, H., Gaza-Bulseco, G., Xiang, T. & Chumsae, C. Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody. Mol. Immunol. 45, 701\u2013708 (2008).","journal-title":"Mol. Immunol."},{"key":"9789_CR48","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1021\/bi702238b","volume":"47","author":"D Liu","year":"2008","unstructured":"Liu, D. et al. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 47, 5088\u20135100 (2008).","journal-title":"Biochemistry"},{"key":"9789_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1124\/dmd.106.011734","volume":"35","author":"A Datta-Mannan","year":"2007","unstructured":"Datta-Mannan, A. et al. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab. Dispos. Biol. Fate Chem. 35, 86\u201394 (2007).","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"9789_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157\u2013159 (2010).","journal-title":"Nat. Biotechnol."},{"key":"9789_CR51","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1124\/dmd.109.031310","volume":"38","author":"R Deng","year":"2010","unstructured":"Deng, R. et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-alpha antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab. dispos. Biol. Fate Chem. 38, 600\u2013605 (2010).","journal-title":"Drug Metab. dispos. Biol. Fate Chem."},{"key":"9789_CR52","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/0008-5472.CAN-09-4580","volume":"70","author":"YA Yeung","year":"2010","unstructured":"Yeung, Y. A. et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res. 70, 3269\u20133277 (2010).","journal-title":"Cancer Res."},{"key":"9789_CR53","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.1074\/jbc.C300470200","volume":"279","author":"PR Hinton","year":"2004","unstructured":"Hinton, P. R. et al. Engineered human IgG antibodies with longer serum half-lives in primates.  J. Biol. Chem. 279, 6213\u20136216 (2004).","journal-title":"J. Biol. Chem."},{"key":"9789_CR54","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","volume":"169","author":"WF Dall\u2019Acqua","year":"2002","unstructured":"Dall\u2019Acqua, W. F. et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 169, 5171\u20135180 (2002).","journal-title":"J. Immunol."},{"key":"9789_CR55","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6","volume":"29","author":"JK Kim","year":"1999","unstructured":"Kim, J. K. et al. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur. J. Immunol. 29, 2819\u20132825 (1999).","journal-title":"Eur. J. Immunol."},{"key":"9789_CR56","doi-asserted-by":"publisher","unstructured":"Gasteiger, E. et al. Protein identification and analysis tools on the ExPASy server. The Proteomics Protocols Handbook. https:\/\/doi.org\/10.1385\/1-59259-890-0:571 (2005).","DOI":"10.1385\/1-59259-890-0:571"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09789-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09789-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09789-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:05:34Z","timestamp":1775743534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09789-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9789"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-09789-3","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.I., R.O., T.Y., L.H., Y.T., and T.I. are employees of Tosoh Corporation. The other authors declare no competing financial interests. All the authors declare no non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"513"}}